BGM1812 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
BGM1812 is a drug that acts on both amylin and calcitonin receptors, from the Chinese company BrightGene. It was built by changing the structure of petrelintide. One chemistry paper reports animal and lab results. Two early safety studies are recruiting in China and the United States. No human data have been published.
Evidence grade for BGM1812: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 1 completed trial, none stating how many people. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 1
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 0 people given it
1 effects reported, 1 unwanted, by people using it, not a trial
Goal pages: Fat loss and metabolism
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
BGM1812 is a lab-made peptide for weight loss from BrightGene, a Chinese company. It works on two fullness signals, amylin and calcitonin. It was built by changing another drug, petrelintide. It is in its first tests in people. It is not approved.
What people take it for
- Weight loss.
- Eating less by feeling full sooner.
What studies in people showed
Nobody has published any human results. Two small safety studies, about 60 people each, are listed in the United States and China. Both only count side effects. Neither has posted results. The only data are animal and lab results in the company's own chemistry paper. That paper gives no numbers for how much weight animals lost. Petrelintide, the drug it came from, has its own results in people. Those belong to petrelintide, not to this one.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
The bad
- There are no human results on this page, so its side effects in people are not known.
Where these come from: There are no user reports or human results on this page to draw from.
My bottom line
This is a chemistry paper and two study numbers. There is nothing here a person should act on. Wait for real results.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals BGM1812 has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Losing weightno headcount stated · 1 study
35 of the 36 indexed goals have no study of any kind behind BGM1812
No study in people, animals or cells on this page reports a result for these. That does not prove BGM1812 does nothing for them. It does mean anything you have heard about BGM1812 and one of these did not come from a study cited here.
Show full evidence
What is BGM1812?
BGM1812 is a drug that acts on both amylin and calcitonin receptors, from the Chinese company BrightGene. It was built by changing the structure of petrelintide. One chemistry paper reports animal and lab results. Two early safety studies are recruiting in China and the United States. No human data have been published.
BGM1812 is a peptide made by BrightGene Bio-Medical Technology in Suzhou, China, for obesity. It switches on both amylin and calcitonin receptors, a type of drug called a DACRA. Its only paper is the discovery paper in the Journal of Medicinal Chemistry (July 2025). That paper says it came from three rounds of design changes, starting from petrelintide, a long-lasting amylin drug that was then in mid-stage testing. The team used computer modelling of how the molecule moves, because there was little data on how shape links to effect. Two tweaks that add small chemical groups (methylation) gave a molecule the authors say lasts longer, is more stable, dissolves better and works better, in a dish and in animals. The summary gives no animal species, group sizes or size of effect. The paper is chemistry, not a study built to describe a drug.
Two early studies are registered, and both were listed as recruiting on 11 September 2026. NCT07224399 is at one site in the United States. It gives single and repeated rising doses, or a dummy injection, to adults who are normal weight to obese but otherwise healthy, and nobody knows who gets which. It started on 9 October 2025, aims for about 60 people, and had its main measurement point set for May 2026. NCT07294235 is in China. It gives single and repeated doses, or a dummy injection, to healthy and overweight or obese people without diabetes, assigned by chance. It started on 5 December 2025, aims for about 60 people, and had its main measurement point set for March 2026. Both count side effects as their main goal. Both main measurement dates had passed at the time of writing, yet both still read recruiting. Neither record had been updated since December 2025. No results have been posted.
There are no human data. Any claim about BGM1812 and weight is, at most, an animal result reported in a chemistry paper. It is still being tested and is not approved anywhere.
How does BGM1812 work?
Amylin receptors are built from the calcitonin receptor plus helper proteins (RAMPs). A dual amylin and calcitonin drug switches on both the amylin receptor pairs and the calcitonin receptor on its own. Whether any of what follows holds for BGM1812 in people is unknown. In animals, drugs of this type cut food intake and body weight by acting on fullness circuits in the hindbrain, and they slow the stomach. The field's working idea, reviewed in 2026, is that hitting the calcitonin receptor may make these drugs work better, while also changing how much nausea and food aversion they cause. The discovery paper says BGM1812 was designed from petrelintide's structure, with small chemical groups added at spots picked by computer modelling. It reports that BGM1812 lasted longer, was more stable, dissolved better and worked better than petrelintide, in a dish and in animals. The summary does not give the species, the model, the doses or the size of any effect. No figure for how long it lasts, how strongly it hits its receptors, or how much weight animals lost is available in a form this page can report.
What have studies in people found about BGM1812?
None published. Two early safety studies of about 60 people each were listed as recruiting in September 2026, and neither has posted results. No person's response to BGM1812 has been reported anywhere.
What this does not tell you: Everything. How it acts in people, how well they tolerate it, how long it lasts, and any effect on weight are all unknown. The only data are animal and lab results, summed up without numbers in a chemistry paper by the company that owns it. Petrelintide's early human results describe the parent molecule, not this one.
The state of the research
BGM1812 is at the earliest stage a drug can be and still have a study number. The record is one chemistry paper written by the company and two registry entries. That is normal for a drug that entered first human testing in late 2025. The paper's framing is worth reading carefully. It presents BGM1812 as an improved version of petrelintide, a rival company's molecule whose early human data are now published. And it builds its case on computer modelling rather than on measured receptor shapes because, as the authors say, data linking shape to effect for this drug family were lacking.
Both studies' main measurement dates had passed at the time of writing, yet both still read recruiting. Neither record had been updated in nine months. That is common for small early studies and is not a sign of a problem. But it means the registry cannot tell you right now whether the studies are running, finished or delayed. When results appear, they will be safety data, and data on how the body handles the drug, from around 120 healthy or overweight volunteers. They will not show whether it works. Until then, the accurate description of BGM1812's effect on weight is an animal result whose size has not been published.
The evidence, in charts
Fig. 1a · how many people
3studies in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
3 of 5 sources here are studies in people. The rest are not.
- Study in people · done in people360%
- Animal study · done in animals120%
- Review of studies · sums up other studies120%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2025 and 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- Not on file
- Half-life
- None on file
- Chain length
- None on file
No amino acid sequence is on file for BGM1812, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2025Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women
This first test of BGM1812 in people is still running. It plans to enrol 60 healthy adults, some of them carrying extra weight, at one site in the United States. Nobody involved will know who gets the drug. It started in October 2025 and the main measurement point is May 2026. What it counts is side effects. BrightGene is the sponsor. No results have been posted, and none are due for a while.
Phase 1, single-centre, double-blind, placebo-controlled dose escalation, United States. Sponsor BrightGene. Started 9 October 2025, estimated 60 participants, primary completion 15 May 2026. Primary outcome: number of treatment adverse events. Listed as recruiting, last updated November 2025; no results posted.
- Study in people2025A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants
A second early trial of BGM1812 is recruiting in China and has published nothing. It plans to enrol 60 healthy and overweight adults, given single and repeated doses. Nobody involved will know who gets the drug. It started in December 2025 with a main measurement point of March 2026. BrightGene is the sponsor. Two small safety studies in healthy volunteers is the entire human record for this compound.
Phase 1, randomised, double-blind, placebo-controlled, single and multiple doses, China. Sponsor BrightGene. Started 5 December 2025, estimated 60 participants, primary completion 2 March 2026. Primary outcome: participants with adverse events and serious adverse events. Listed as recruiting, last updated December 2025; no results posted.
- Study in people2026Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials
Petrelintide took off weight in early trials, and it is not the same drug as the one on this page. Healthy and overweight adults took weekly injections or a dummy. The body took about ten days to clear half of a dose, which supports weekly dosing. After four months, weight was down by up to 8.6 percent. Nausea was somewhat more common on the drug. BGM1812 was built from petrelintide, but these are petrelintide results. They say nothing directly about BGM1812.
Petrelintide, the parent scaffold from which BGM1812 was derived, in randomised placebo-controlled phase 1 trials: half-life about 10 days, weight reduction up to 8.6 percent after 16 weeks of weekly dosing, nausea in 16.7 to 33.3 percent against 16.7 percent on placebo. These are petrelintide data and say nothing directly about BGM1812.
- Review of studies2026Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
A review of long-lasting amylin drugs, and of drugs that hit both amylin and calcitonin receptors, now being tested in people. Its summary does not mention BGM1812.
Class review of long-acting amylin and dual amylin and calcitonin receptor agonists in clinical development. Its abstract does not mention BGM1812.
- Animal study2025Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
In a dish and in animals. BrightGene's chemistry paper describes building BGM1812 from petrelintide through three rounds of design changes guided by computer modelling. Its summary says the new molecule lasted longer, was more stable, dissolved better and worked better, in a dish and in animals. It gives no species, doses or size of effect. It is the only paper on the drug, and the company wrote it.
Medicinal chemistry paper from BrightGene. BGM1812 was derived from petrelintide through three rounds of structure-based modification and molecular dynamics guided methylation. The abstract reports improved half-life, stability and solubility and enhanced efficacy in vitro and in vivo without stating species, doses or effect sizes. The only publication on the compound; industry authored.
Where to buy BGM1812
No seller we track lists BGM1812 yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has BGM1812 been tested in people?
Yes. 0 people given it across 1 completed trial cited here, 0 of which found nothing. BGM1812 is a drug that acts on both amylin and calcitonin receptors, from the Chinese company BrightGene. It was built by changing the structure of petrelintide. One chemistry paper reports animal and lab results. Two early safety studies are recruiting in China and the United States. No human data have been published.
What is the BGM1812 dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 0 people given it
Is BGM1812 FDA-approved?
Not approved. Two early safety studies (NCT07224399 in the United States, NCT07294235 in China) are listed as signing people up. Both mainly measure safety. No results posted, and no data in people published.
What is BGM1812?
A peptide from BrightGene, a Chinese company, that switches on both amylin and calcitonin receptors. It was designed by changing the structure of petrelintide. It is in early studies in China and the United States and is not approved anywhere.
Does it cause weight loss in people?
Nobody knows. No human data have been published. The two early studies measure safety and side effects as their main goal, and neither has posted results. The only claim that it works is an animal result in the discovery paper. The paper's summary does not give the species, the dose or the size of the effect.
How does it relate to petrelintide?
The discovery paper says BGM1812 came from petrelintide's structure, through three rounds of changes meant to make it stronger, longer-lasting, more stable and easier to dissolve. Petrelintide itself has published early human data showing up to 8.6 percent weight loss at 16 weeks. Those results belong to petrelintide and do not carry over to BGM1812.